期刊
CANCER PREVENTION RESEARCH
卷 4, 期 10, 页码 1626-1635出版社
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1940-6207.CAPR-11-0090
关键词
-
类别
资金
- German Research Foundation [Graduiertenkolleg 793]
- European Commission (DG-SANCO)
- Ligue contre le Cancer, Mutuelle Generale de l' Education Nationale, Institut National de la Sante et de la Recherche Medicale (France)
- Danish Cancer Society (Denmark)
- Deutsche Krebshilfe
- Deutsches Krebs-forschungszentrum
- Federal Ministry of Education and Research (Germany)
- Stavros Niarchos Foundation
- Hellenic Health Foundation
- Italian Association for Research on Cancer (AIRC)
- National Research Council (Italy)
- Dutch Ministry of Public Health, Welfare and Sports (VWS)
- Netherlands Cancer Registry (NKR)
- LK Research Funds
- Dutch Prevention Funds
- Dutch ZON (Zorg Onderzoek Nederland)
- World Cancer Research Fund (WCRF)
- Statistics Netherlands (The Netherlands)
- ERC-2009-AdG 232997
- Nordforsk, (Norway)
- Health Research Fund (FIS)
- Regional Government of Andalucia
- Regional Government of Asturias
- Regional Government of Basque Country
- Regional Government of Murcia
- Regional Government of Navarra
- ISCIII RETIC (Spain) [RD06/0020]
- Swedish Cancer Society
- Swedish Scientific Council
- Regional Government of Skane and Vasterbotten (Sweden)
- Cancer Research UK
- Medical Research Council
- Stroke Association
- British Heart Foundation
- Department of Health
- Wellcome Trust (United Kingdom)
- Hellenic Ministry of Health. (Greece)
- Medical Research Council [G0401527, G1000143] Funding Source: researchfish
Prediagnostic endogenous sex steroid hormone levels have well established associations with overall risk of breast cancer. While evidence toward the existence of distinct subtypes of breast cancer accumulates, few studies have investigated the associations of sex steroid hormone levels with risk of hormone receptor [estrogen receptor (ER) and/or progesterone receptor (PR)] defined breast cancer. In a case-control study nested within the EPIC cohort (European Prospective Investigation into Cancer and Nutrition), estradiol, testosterone, and sex hormone-binding globulin levels were measured in prediagnostic serum samples from postmenopausal women not using hormone replacement therapy at blood donation. A total of 554 women who developed invasive breast cancer with information on receptor status were matched with 821 control subjects. Conditional logistic regression models estimated breast cancer risk with hormone concentrations according to hormone receptor status of the tumor. Sex steroid hormones were associated with risks of not only ER+PR+ breast cancer [estradiol OR for highest vs. lowest tertile = 2.91 (95% CI: 1.62-5.23), P-trend 0.002; testosterone OR = 2.27 (95% CI: 1.35-3.81), P-trend 0.002] but also of ER-PR- breast cancer [estradiol OR = 2.11 (95% CI: 1.00-4.46), P-trend = 0.05; testosterone OR = 2.06 (95% CI: 0.95-4.46), P-trend = 0.03], with associations appearing somewhat stronger in the receptor-positive disease. Serum androgens and estrogens are associated with risks of both hormone receptor-negative as well as receptor-positive breast tumors. Further research is needed to establish through which molecular pathways, and during which evolutionary stages of development, androgens and estrogens can promote the occurrence of both receptor-positive and -negative clinical breast tumors. Cancer Prev Res; 4(10); 1626-35. (C)2011 AACR.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据